EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Introducing the four dimensions 4D migraine scale: A composite score proposal evaluating migraine severity and treatment efficacy

Patrizio Pasqualetti iD, Claudia Altamura iD, Luisa Fofi iD, Luigi Francesco Iannone iD, Marilena Marcosano iD, Giulia Bellini, Marina Romozzi iD, Sabina Cevoli, Gian Camillo Manzoni, Fabrizio Vernieri iD

Cephalalgia · 2025

DOI: 10.1177/03331024251398020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cephalalgia, 2025. Verfasst von Patrizio Pasqualetti und 9 weiteren Autor:innen. Beteiligte Einrichtung: Section of Health Statistics and Biometry, Department of Public Health and Infectious Diseases, Sapienza University of Rome, Roma, Italy. Hauptthemen laut MEDLINE: Migraine Disorders, Severity of Illness Index. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sapienza University of Rome.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Different parameters are currently used to evaluate migraine frequency and disability. We aimed to formulate a composite scale including the most relevant clinical measures to better evaluate the burden of migraine.

Methods

To create the composite four dimensions 4D migraine scale, we selected the most commonly used outcome measures: monthly migraine days (MMDs), number of monthly acute medications (MAMs), pain intensity (by Numerical Rating Score, NRS) and Migraine Disability Assessment (MIDAS) Score. Each parameter was categorized in different levels: five for MMDs, seven for MAMs, five for NRS and six for MIDAS to cover the entire empirical range of each variable. First, the relative weight of each level per parameter was rated by 197 migraine patients and 118 headache experts using Conjoint Analysis. Secondly, we applied the 4D migraine score to a sample of patients treated with galcanezumab. We assessed its concurrent validity for the scale's single parameters and the Head Impact Test HIT-6, an external patient-reported outcome measure.

Results

There was a substantial agreement between clinicians and patients about the weight of each parameter in terms of Relative Importance (RI). For both categories, MMDs were the most relevant attribute (RI: 34% for clinicians, 32% for patients) and pain intensity NRS the least important (RI: 14% vs 13%). Though marginally, MIDAS was more important than MAMs for patients (29% vs. 26%), while for clinicians the relevance of these two attributes was almost equal (26% and 27%). In terms of the utility assigned to each level, strong agreement was confirmed between clinicians and patients. According to the utilities implicitly attributed by participants to the chosen representative levels of the four parameters, four different statistical models were derived, allowing to compute utilities from all possible values of MMDs, MAMs, NRS and MIDAS and finally a unique 4D migraine score for every possible patient, ranging from 0 (without migraine) to 100 (with the most severe migraine). The 4D score was valid in terms of sensitivity to changes and showed concurrent validity with respect to HIT-6.

Conclusion

The 4D migraine scale, based on the preference weights of both clinicians and patients, could be useful to fully quantify the migraine burden and the efficacy of a treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersSeverity of Illness IndexHumansMaleFemaleAdultMiddle AgedTreatment OutcomePain MeasurementDisability Evaluation

Stichwörter der Autor:innen

composite scorediscrete choice experimentmigrainepatient preferencepreventive treatment

Autor:innen und Institutionen

  • Section of Health Statistics and Biometry, Department of Public Health and Infectious Diseases, Sapienza University of Rome, Roma, Italy.
  • Headache and Neurosonology Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy.
  • Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Roma, Italy.
  • Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico Di Modena, Modena, Italy.
  • Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
  • Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Roma, Italy.

ORCID-Profile: Patrizio Pasqualetti, Claudia Altamura, Luisa Fofi, Luigi Francesco Iannone, Marilena Marcosano, Marina Romozzi, Fabrizio Vernieri

Förderung

  • Sapienza University of Rome

Zitieren

APA

Pasqualetti, P., Altamura, C., Fofi, L., Iannone, L. F., Marcosano, M., Bellini, G., Romozzi, M., Cevoli, S., Manzoni, G. C., & Vernieri, F. (2025). Introducing the four dimensions 4D migraine scale: A composite score proposal evaluating migraine severity and treatment efficacy. Cephalalgia. https://doi.org/10.1177/03331024251398020

Vancouver

Pasqualetti P, Altamura C, Fofi L, Iannone LF, Marcosano M, Bellini G, et al. Introducing the four dimensions 4D migraine scale: A composite score proposal evaluating migraine severity and treatment efficacy. Cephalalgia. 2025. doi:10.1177/03331024251398020

BibTeX
@article{Pasqualetti2025,
  author = {Pasqualetti, Patrizio and Altamura, Claudia and Fofi, Luisa and Iannone, Luigi Francesco and Marcosano, Marilena and Bellini, Giulia and Romozzi, Marina and Cevoli, Sabina and Manzoni, Gian Camillo and Vernieri, Fabrizio},
  title = {Introducing the four dimensions 4D migraine scale: A composite score proposal evaluating migraine severity and treatment efficacy},
  journal = {Cephalalgia},
  year = {2025},
  doi = {10.1177/03331024251398020}
}
Kostenlos starten →